Boston Scientific reported second-quarter revenue of $5.44 billion, beating analyst estimates of $5.36 billion, but issued third-quarter revenue guidance of $5.27 billion that fell short of the $5.39 billion consensus. The company lowered its full-year adjusted earnings per share guidance to $3.30, a 2.2% reduction, citing unexpected slowdowns in its WATCHMAN left atrial appendage closure device and U.S. Electrophysiology business. CEO Michael Mahoney pointed to rapid shifts in clinical adoption and competitive pressures, particularly from pulsed-field ablation devices, as factors that will likely persist into 2027. A new restructuring program targeting $500 million in run-rate savings by 2029 was announced, with meaningful margin expansion not expected until 2028. Management highlighted seven major product launches planned for 2028 and beyond as key catalysts for a return to higher growth.
Boston Scientific CorpUnexpected slowdowns in WATCHMAN and Electrophysiology, with competitive pressures from pulsed-field ablation devices, led to lowered guidance.